Vancouver, British Columbia-based biotherapeutics provider Zymeworks Inc. has raised $58.5 million for its IPO after pricing its 4.5 million shares at $13 per share. Zymeworks’ pre-IPO backers include BDC Capital, Lumira Capital, CTI Life Sciences Fund, Fonds de solidarité FTQ, Perceptive Advisors, Teralys Capital, Northleaf Venture Catalyst Fund, Brace Pharma Capital and Merlin Nexus.